Guri, Yakir and Hall, Michael N.. (2016) mTOR Signaling Confers Resistance to Targeted Cancer Drugs. Trends in Cancer, 2 (11). pp. 688-697.
PDF
- Published Version
Restricted to Repository staff only 1800Kb |
Official URL: http://edoc.unibas.ch/51836/
Downloads: Statistics Overview
Abstract
Cancer is a complex disease and a leading cause of death worldwide. Extensive research over decades has led to the development of therapies that target cancer-specific signaling pathways. However, the clinical benefits of such drugs are at best transient due to tumors displaying intrinsic or adaptive resis- tance. The underlying compensatory pathways that allow cancer cells to cir-cumvent a drug blockade are poorly understood. We review here recent studies suggesting that mammalian TOR (mTOR) signaling is a major compensatory pathway conferring resistance to many cancer drugs. mTOR-mediated resis-tance can be cell-autonomous or non-cell-autonomous. These findings suggest that mTOR signaling should be monitored routinely in tumors and that an mTOR inhibitor should be considered as a co-therapy.
Faculties and Departments: | 05 Faculty of Science > Departement Biozentrum > Growth & Development > Biochemistry (Hall) |
---|---|
UniBasel Contributors: | Hall, Michael N. |
Item Type: | Article, refereed |
Article Subtype: | Research Article |
Publisher: | Elsevier |
ISSN: | 2405-8033 |
Note: | Publication type according to Uni Basel Research Database: Journal article |
Language: | English |
Related URLs: | |
Identification Number: | |
edoc DOI: | |
Last Modified: | 05 Jun 2019 08:19 |
Deposited On: | 13 Jul 2017 09:40 |
Repository Staff Only: item control page